Novo Nordisk signs $2.6 billion deal with China's Hengrui for oral GLP-1/GIP candidate
Novo Nordisk announced a licensing agreement with Chinese drugmaker Hengrui Pharmaceuticals, paying $300 million upfront for rights to a preclinical GLP-1/GIP dual-receptor agonist.
The candidate, called HRS-1596, is designed for once-weekly oral dosing and aims to suppress appetite, stimulate insulin secretion and improve insulin sensitivity for obesity, type 2 diabetes and other metabolic diseases.
Hengrui has secured Chinese regulatory clearance to begin phase 1 trials, and the agreement includes milestone payments that could lift the total value to $2.6 billion. Novo said the oral format could offer a convenience edge over current injectable GLP-1/GIP therapies.
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui”
read at Fierce Biotech ↗
comments(0)
5-min edit window · permanent after that